Literature DB >> 29980532

Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas.

Haibo Zhu1, Jing Guo1, Yutao Shen1, Wei Dong1, Hua Gao1, Yazhou Miao1, Chuzhong Li1,2,3,4, Yazhuo Zhang5,2,3,4.   

Abstract

Purpose: To explore the molecular mechanism and prognosis of bone-invasive pituitary adenomas (BIPA).Experimental design: A total of 274 patients with pituitary adenomas were followed up. Transcriptomic microarrays analysis was performed on 10 pituitary adenomas, including five BIPAs and five non-bone-invasive pituitary adenomas (NBIPA). The targeted molecular markers were validated by qRT-PCR, IHC, ELISA, and osteoclast differentiation.
Results: Clinical variable analyses revealed a significant correlation between bone invasion and female sex, large tumor volume, non-gross total resection (NGTR), and tumor regrowth. BIPAs had worse progression-free survival (PFS) than did NBIPAs in the NGTR and nonfunctional pituitary adenoma (NFPA) groups. Gene ontology functional and KEGG pathway analyses showed that the biological processes and pathways were primarily immune and inflammatory pathways. Pathway act work showed that osteoclast differentiation pathway was significantly implicated in the pathway network. BIPAs had higher expression of TNFα than that of NBIPAs on IHC. In vitro, TNFα could induce RAW264.7 cells to differentiate into mature osteoclasts, leading to bone destruction. NR_033258, lncRNA SNHG24, miR-181c-5p, and miR-454-3p can regulate TNFα expression.Conclusions: BIPAs had worse PFS than did NBIPAs in the NGTR and NFPA groups. Inflammatory and immune factors play an important role in BIPAs. TNFα can directly induce osteoclast differentiation in BIPAs. NR_033258, lncRNA SNHG24, miR-181c-5p, and miR-454-3p can regulate TNFα expression. TNFα and its related lncRNAs and miRNAs represent potential therapeutic targets for bone-invasive pituitary adenomas in the future. Clin Cancer Res; 24(22); 5757-66. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29980532     DOI: 10.1158/1078-0432.CCR-18-0472

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

Review 1.  Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions.

Authors:  Liang Lu; Xueyan Wan; Yu Xu; Juan Chen; Kai Shu; Ting Lei
Journal:  Diagnostics (Basel)       Date:  2022-04-13

2.  Case Report: Extensive Temporal Bone Invasion in a Giant Vestibular Schwannoma.

Authors:  Fang Lyu; Jinlu Gan; Haijun Wang; Hongyang Zhao; Lei Wang; Fangcheng Zhang
Journal:  Front Surg       Date:  2022-05-25

3.  Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma.

Authors:  Wen Lyu; Xu Fei; Cheng Chen; Yuqun Tang
Journal:  Gland Surg       Date:  2021-02

Review 4.  Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

Authors:  Siqi Wen; Chunling Li; Xianquan Zhan
Journal:  EPMA J       Date:  2022-02-17       Impact factor: 6.543

5.  Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.

Authors:  Tomasz M Grzywa; Klaudia Klicka; Beata Rak; Dawid Mehlich; Filip Garbicz; Grzegorz Zieliński; Maria Maksymowicz; Emir Sajjad; Paweł K Włodarski
Journal:  Endocrine       Date:  2019-06-04       Impact factor: 3.633

6.  LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis.

Authors:  Peng Zhao; Jianhua Cheng; Bin Li; Ding Nie; Hongyun Wang; Chuzhong Li; Songbai Gui; Yazhuo Zhang
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

7.  lncRNA MEG3 inhibits pituitary tumor development by participating in cell proliferation, apoptosis and EMT processes.

Authors:  Xuejian Wang; Xiangdong Li; Zhifeng Wang
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

Review 8.  Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment.

Authors:  Alicja Nowaczyk; Dawid Szwedowski; Ignacio Dallo; Jacek Nowaczyk
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

Review 9.  Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.

Authors:  Ding Nie; Qiuyue Fang; Bin Li; Jianhua Cheng; Chuzhong Li; Songbai Gui; Yazhuo Zhang; Peng Zhao
Journal:  World J Surg Oncol       Date:  2021-06-05       Impact factor: 2.754

Review 10.  Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.

Authors:  Vinaya Srirangam Nadhamuni; Márta Korbonits
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.